» Articles » PMID: 27713091

National Institutes of Health Blood and Marrow Transplant Late Effects Initiative: The Healthcare Delivery Working Group Report

Abstract

Hematopoietic cell transplantation (HCT) survivors are at risk for development of late complications and require lifelong monitoring for screening and prevention of late effects. There is an increasing appreciation of the issues related to healthcare delivery and coverage faced by HCT survivors. The 2016 National Institutes of Health Blood and Marrow Transplant Late Effects Initiative included an international and broadly representative Healthcare Delivery Working Group that was tasked with identifying research gaps pertaining to healthcare delivery and to identify initiatives that may yield a better understanding of the long-term value and costs of care for HCT survivors. There is a paucity of literature in this area. Critical areas in need of research include pilot studies of novel and information technology supported models of care delivery and coverage for HCT survivors along with development and validation of instruments that capture patient-reported outcomes. Investment in infrastructure to support this research, such as linkage of databases including electronic health records and routine inclusion of endpoints that will inform analyses focused around care delivery and coverage, is required.

Citing Articles

International recommendations for screening and preventative practices for long-term survivors of transplantation and cellular therapy: a 2023 update.

Rotz S, Bhatt N, Hamilton B, Duncan C, Aljurf M, Atsuta Y Bone Marrow Transplant. 2024; 59(6):717-741.

PMID: 38413823 PMC: 11809468. DOI: 10.1038/s41409-023-02190-2.


International Recommendations for Screening and Preventative Practices for Long-Term Survivors of Transplantation and Cellular Therapy: A 2023 Update.

Rotz S, Bhatt N, Hamilton B, Duncan C, Aljurf M, Atsuta Y Transplant Cell Ther. 2024; 30(4):349-385.

PMID: 38413247 PMC: 11181337. DOI: 10.1016/j.jtct.2023.12.001.


Over 20% of patients report excessive alcohol use pre-transplant.

Kirsch J, Hogan W, Patnaik M, Ehlers S Bone Marrow Transplant. 2023; 58(5):581-583.

PMID: 36693926 DOI: 10.1038/s41409-023-01921-9.


Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.

Fitzhugh C, Volanakis E, Idassi O, Duberman J, DeBaun M, Friedman D J Clin Med. 2022; 11(11).

PMID: 35683502 PMC: 9181610. DOI: 10.3390/jcm11113118.


Development of an integrated model of care for allogeneic stem cell transplantation facilitated by eHealth-the SMILe study.

Leppla L, Schmid A, Valenta S, Mielke J, Beckmann S, Ribaut J Support Care Cancer. 2021; 29(12):8045-8057.

PMID: 34224016 PMC: 8550349. DOI: 10.1007/s00520-021-06328-0.


References
1.
Berwick D, Nolan T, Whittington J . The triple aim: care, health, and cost. Health Aff (Millwood). 2008; 27(3):759-69. DOI: 10.1377/hlthaff.27.3.759. View

2.
Gajewski J, Foote M, Tietjen J, Melson B, Simmons A, Champlin R . Blood and marrow transplantation compensation: perspective in payer and provider relations. Biol Blood Marrow Transplant. 2004; 10(7):427-32. DOI: 10.1016/j.bbmt.2004.03.004. View

3.
Oeffinger K, Argenbright K, Levitt G, McCabe M, Anderson P, Berry E . Models of cancer survivorship health care: moving forward. Am Soc Clin Oncol Educ Book. 2014; :205-13. DOI: 10.14694/EdBook_AM.2014.34.205. View

4.
McCabe M, Partridge A, Grunfeld E, Hudson M . Risk-based health care, the cancer survivor, the oncologist, and the primary care physician. Semin Oncol. 2013; 40(6):804-12. PMC: 4465133. DOI: 10.1053/j.seminoncol.2013.09.004. View

5.
Howell D, Hack T, Oliver T, Chulak T, Mayo S, Aubin M . Models of care for post-treatment follow-up of adult cancer survivors: a systematic review and quality appraisal of the evidence. J Cancer Surviv. 2012; 6(4):359-71. DOI: 10.1007/s11764-012-0232-z. View